We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc | NASDAQ:REGN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 12.88 | 1.19% | 1,094.99 | 1,091.00 | 1,100.00 | 1,100.08 | 1,079.0855 | 1,087.89 | 282,347 | 22:05:20 |
From Jul 2021 to Jul 2024
By Colin Kellaher
Regeneron Pharmaceuticals Inc. and Sanofi SA on Friday said a Phase 3 study of their blockbuster eczema drug Dupixent in the chronic skin condition prurigo nodularis met its primary and all secondary endpoints.
The companies said Dupixent significantly reduced itch at 12 weeks, while nearly three times as many Dupixent patients experienced reductions in both itch and skin lesions at 24 weeks compared to placebo.
Regeneron and Sanofi said prurigo nodularis is the sixth disease where Dupixent has shown positive Phase 3 results, adding that they plan to begin regulatory submissions next year.
Regeneron, of Tarrytown, N.Y., created Dupixent and markets it jointly in the U.S. with France's Sanofi under a 2007 collaboration agreement. Sanofi markets the product internationally.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 22, 2021 06:24 ET (10:24 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Regeneron Pharmaceuticals Chart |
1 Month Regeneron Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
